Loading clinical trials...
Loading clinical trials...
DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck
Conditions
Interventions
Radiotherapy
Zalutumumab
Locations
1
Denmark
Department of Experimental Clinical Oncology, Aarhus University Hospital
Aarhus, Denmark
Start Date
November 1, 2007
Primary Completion Date
July 1, 2012
Completion Date
November 1, 2016
Last Updated
November 25, 2016
NCT05789316
NCT04865731
NCT00256295
NCT02880072
NCT02558387
NCT01252498
Lead Sponsor
Danish Head and Neck Cancer Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions